Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW679769 in major depressive disorder
NCT00102492Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of casopitant in major depressive disorder (MDD), sponsored by GSK. Started Oct 2004; status: completed.
02
Drugs
casopitant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00102492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00102492.